San Diego – January 29, 2015 – Cooley advised Ionis Pharmaceuticals Inc. on a global collaboration, option and license agreement with Janssen Biotech Inc. to discover and develop antisense drugs to treat autoimmune disorders of the GI tract.
Pursuant to the agreement, Ionis will receive $35 million in up-front payments for three programs, including a payment to initiate human lead optimization on the first collaboration target. Isis is also eligible to receive nearly $800 million in development, regulatory and sales milestone payments and license fees for the programs.
Ionis is the leader in antisense drug discovery and development, exploiting a proven, novel drug discovery platform designed to generate a pipeline of first-in-class drugs.
Partner Jane Adams, a member of Cooley's life sciences partnering and licensing group, led the Cooley team that advised Ionis Pharmaceuticals on the collaboration.
About Cooley LLP
Cooley's lawyers solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, often where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.